Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma By Ogkologos - October 24, 2025 287 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENRICH study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Mom Wants Disney To Ban Childless Adults From Their Theme Parks July 29, 2019 Extended Follow-Up Further Supports Lenvatinib Plus Pembrolizumab in Patients with Previously... April 20, 2023 Scientists reveal how air pollution can cause lung cancer in people... September 10, 2022 Por qué no voy a “superar” los efectos a largo plazo... July 20, 2021 Load more HOT NEWS Sotorasib Shows Increase in PFS and a More Favourable Safety Compared... Young Breast Cancer Survivors Without a Germline Pathogenic Variant Have a... Beating cancer by improving the public’s health: the road ahead in... Cancer in My Community: Addressing Regional Cancer Disparities in Peru
